- Home
- HLVX vs SRZN Comparison
HLVX vs SRZN Comparison
Compare HLVX & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- SRZN
- Stock Information
- Founded
- HLVX 2020
- SRZN 2015
- Country
- HLVX United States
- SRZN United States
- Employees
- HLVX N/A
- SRZN N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- HLVX Health Care
- SRZN Health Care
- Exchange
- HLVX Nasdaq
- SRZN Nasdaq
- Market Cap
- HLVX 83.7M
- SRZN 82.8M
- IPO Year
- HLVX 2022
- SRZN N/A
- Fundamental
- Price
- HLVX $1.87
- SRZN $8.49
- Analyst Decision
- HLVX Hold
- SRZN Strong Buy
- Analyst Count
- HLVX 5
- SRZN 2
- Target Price
- HLVX $2.33
- SRZN $38.50
- AVG Volume (30 Days)
- HLVX 219.8K
- SRZN 13.0K
- Earning Date
- HLVX 05-08-2025
- SRZN 05-09-2025
- Dividend Yield
- HLVX N/A
- SRZN N/A
- EPS Growth
- HLVX N/A
- SRZN N/A
- EPS
- HLVX N/A
- SRZN N/A
- Revenue
- HLVX N/A
- SRZN $11,638,000.00
- Revenue This Year
- HLVX N/A
- SRZN N/A
- Revenue Next Year
- HLVX N/A
- SRZN N/A
- P/E Ratio
- HLVX N/A
- SRZN N/A
- Revenue Growth
- HLVX N/A
- SRZN N/A
- 52 Week Low
- HLVX $1.34
- SRZN $5.90
- 52 Week High
- HLVX $15.60
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- HLVX 51.02
- SRZN 49.02
- Support Level
- HLVX $1.82
- SRZN $5.90
- Resistance Level
- HLVX $1.89
- SRZN $8.14
- Average True Range (ATR)
- HLVX 0.07
- SRZN 0.87
- MACD
- HLVX -0.02
- SRZN 0.15
- Stochastic Oscillator
- HLVX 22.73
- SRZN 82.75
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).